Independent writing on medicine, public health and health policy — with a Malaysian and regional perspective. Researched from primary sources and written by Dr Muruga Vadivale, who has been writing about medicine online since 1995. About Kerbside Consult and how I work →
Can We Test a Drug Before Giving It to the Patient?
Researchers propose testing medicines on living models grown from a patient’s own cells, with a computer twin predicting the response, before the patient is treated. This article looks at what has been shown, where the models fall short, and why human clinical trials are not going away.
Read the article →A Third Set of Teeth — What Is Real, and What Is Not Yet?
Posts say scientists are regrowing teeth. The papers and the trial registry say something more careful: a Japanese antibody tested for safety in healthy men, and an enamel coating tested only on extracted teeth.
Eliminated, Until It Wasn’t
Updated with November surveillance: Bangladesh at 238,840 suspected cases and the United States at 5,182 confirmed, the CDC’s latest count. Six corrections are logged in the article.
Nine Weeks at the Kerbside
A guide to all 84 pieces published since 26 August, grouped by subject, with the Vads Corner resource pages that moved alongside them. Updated periodically; every update is logged in the article.
All articles — 2026
November 202611 articles
Summary
Mayo Clinic’s Charles Howe has proposed an “ex vivo clinical trial”: living models grown from a patient’s cells, paired with a computer twin that learns from each result, to test medicines before the patient is exposed. This article explains biological avatars and digital twins, what a 2025 colorectal cancer study and a Mayo sepsis model show, and where the models fall short, and why human clinical trials are not going away. It is careful about the difference between predicting a response and improving a patient’s outcome.
Testing before treatment is an attractive ambition. Predicting correctly is the real achievement.Read the article →Summary
Social media says scientists are regrowing teeth. This article goes back to the record: the USAG-1 antibody TRG035, from the 2021 mouse and ferret work to a completed Phase I safety study in 30 healthy men and a children’s Phase IIa study still awaiting ethics review, and a Nottingham enamel coating tested only on extracted teeth. It sets three Facebook posts against the papers and registry entries, looks at what Malaysian rules say about “regrowth” claims, and offers four questions for reading any such claim. It is careful about the difference between a safety study and a treatment, and between repairing enamel and growing a tooth.
The caveat is usually there somewhere. It just does not travel with the share.Read the article →Summary
A brain–computer interface placed through a vein, not through the skull, has let people with ALS and other severe paralysis control a computer. This article explains how the Stentrode works, what the four-patient SWITCH study and the COMMAND study show about safety, who funded the evidence, and how it compares with other implanted interfaces. It is careful about the difference between a successful implant and a demonstrated improvement in a patient’s life.
Early results are promising, but four patients and no quality-of-life data cannot show lasting benefit.Read the article →Summary
The Poisons Board has reportedly backed exempting liquid nicotine used in vaping from the Poisons List, by secret ballot and without published reasons. This article sets out what is known about nicotine, vaping and quitting smoking, compares what other countries have done, and explains the 2026 High Court ruling on the 2023 exemption. It argues that a secret vote need not mean secret reasons, and asks whether MMA should stay on the Board.
A recommendation, not yet an order. The article asks for the evidence behind it.Read the article →Summary
WHO ended the mpox emergency in September 2025, but transmission continues. Thailand reported 470 cases and three deaths from January to October 2026, and its September update showed clade Ib outnumbering clade II. This article explains how mpox spreads and is diagnosed, what clades are, what Malaysian and regional reporting shows (the Malaysian figures run to March 2026), who is offered vaccination, and why tecovirimat did not show benefit in the PALM007 and STOMP trials. It is careful that a crude case-fatality ratio is not an individual risk.
Reported cases are rising, but the figures cannot be turned into an individual’s risk.Read the article →Summary
Twenty years after Yamanaka’s discovery, partial reprogramming has reached patients. This article explains how the Yamanaka factors work and what mouse studies showed, then looks at ER-100, a three-factor treatment being tested in glaucoma and ischaemic optic neuropathy, and the company-reported results from three patients at Day 56. It is careful about the difference between a well-tolerated first step and a younger patient.
Three patients at 56 days show early tolerability, not rejuvenation.Read the article →Summary
S. Kathiravale, my maternal uncle, was a FIFA football referee, an FIH hockey umpire and a referee instructor. A tribute to a quiet Malaysian sporting pioneer: the finals he officiated in two sports, what the records show, and what is still to be confirmed.
His family lists 18 possible “firsts”. None is confirmed yet, and the article says so.Read the article →Summary
Every medicine has a reason for being prescribed. But does that reason still apply today? How medicines pile up over the years, what the evidence says about deprescribing, why supplements, “anti-ageing” products and herbal remedies need the same questions as any other treatment, and a practical way for families to keep one current list.
Not every medicine should be stopped, and none should be stopped without clinical advice.Read the article →Summary
In July 2026, Nature Medicine published the first human trial of stem cell-derived neural progenitor cells transplanted into the injured spinal cord. Four Japanese men with severe, recent neck injuries each received about two million cells. At one year, two had improved from complete paralysis (AIS A) to a milder grade, one of them with a large gain in leg strength. This article explains why the spinal cord is so hard to repair, where the cells came from, and what the study can and cannot show without a control group, including why the published results do not establish that anyone regained independent walking. It sets the trial against earlier reviews of cell therapy, looks at the question of patients paralysed for years, and compares other approaches such as exoskeletons, brain–computer interfaces and spinal stimulation. It is careful about the difference between a neurological score and a person who can walk.
Encouraging, but four patients and no control group cannot show that the cells caused the recovery.Read the article →Summary
This is not a medical article, and it says so. In 1998 Karl Bushby, a former British paratrooper, set out to walk from the southern tip of South America to Britain under two rules: no transport to advance the journey, and no going home until he arrived on foot. He reached Hull on 2 November 2026, after 28 years. The essay looks at why the walking kept stopping, who paid for the journey, and three crossings (the Bering Strait, the Caspian Sea and the English Channel), none of them made alone. It also counts the cost to his family, and asks why a story about the kindness of strangers belongs in a column about medicine. The illustration is AI-generated and labelled as such.
A feature essay, not a medical article. Details are as reported by the sources cited.Read the article →Summary
In October 2026, a Phase III trial reported that a personalised mRNA treatment, added to pembrolizumab after surgery, reduced the risk of melanoma coming back. This article starts with what mRNA is and why the COVID-19 vaccines were only its first use, then explains how a vaccine made for one patient's tumour differs from a vaccine against an infection. It sets out what the INTerpath-001 trial showed and what it did not, including why a 42% lower risk is not 42% more patients cured, and looks at early pancreatic and breast cancer studies. It also covers safety, the non-vaccine uses of mRNA, and what this could mean for Malaysia. It is careful about the difference between interim results and survival benefit.
A promising result is not yet a proven cure. The full paper is still to come.Read the article →October 202640 articles
Summary
In 2023, surgeons in Seoul implanted a 3D-bioprinted windpipe in a woman in her fifties. This article asks how close we are to printing spare parts for the human body. It separates what is already in clinical use, from 3D-printed airway splints and an FDA-approved engineered blood vessel to cartilage, skin and corneal therapies, from what is still in the lab, including the Korean implant, a Chinese tissue-engineered airway series and an engineered oesophagus in pigs. It also revisits the Macchiarini case. It is careful about the difference between a successful operation and a demonstrated treatment, and between an implant that supports an organ and one that replaces it.
The science deserves excitement. Patients deserve evidence.Read the article →Summary
Eighty-four pieces since 26 August, grouped by subject: outbreaks, haze and heat, health systems and money, ageing and records, frontier science, clinical research, the profession, and essays and tributes. It also lists the Vads Corner resource pages that were added or revised over the same period, and keeps a running update log. It is careful about what a count of pieces does and does not show.
At the kerbside, the question is the same every time: what does the evidence say, and who will tell you?Read the article →Summary
In October 2026, a surgeon at a console in Sydney controlled a Toumai surgical robot about 7,500 kilometres away in Shanghai, cutting and stitching a demonstration kidney. No patient was involved. This article asks what the evidence for remote and robotic surgery actually shows, from Operation Lindbergh in 2001 and a 2026 BMJ randomised trial of telesurgery in 72 patients, to teleoperated humanoid robots in living pigs and a system that completed the evaluated steps on eight excised pig gallbladders. It then turns to Malaysia, where a 5G broadcast of transoral robotic surgery was remote education and not telesurgery, to what happens when the connection fails or the patient bleeds, to who is responsible, and to whether robotic surgery is better surgery or simply more expensive surgery. It is careful about the difference between a demonstration and a clinical trial, and between a step performed on excised tissue and an operation on a patient.
Whatever the technology, the patient must remain at the centre of the operating theatre.Read the article →Summary
In a reply to the Dewan Rakyat on 21 October 2026, the Ministry of Health reported 3,510 resignations among permanent and contract medical officers during 2024–2026, and 13,072 vacant doctor posts as at 30 June 2026. This article asks what those figures can and cannot tell us. It starts with where doctors went, with the private sector the largest recorded destination, and with what the Malaysian Medical Association says a permanent post must come with. It then looks at specialist training and who gets selected, a personal account of postgraduate study in Singapore in 1989–1990, what medical students say they intend to do, and Singapore’s open recruitment of overseas-trained doctors. It ends with what the Ministry should publish. It is careful about the difference between a resignation and an emigration, and between a vacant post and a shortage of doctors.
Public healthcare cannot assume its doctors’ commitment; it has to earn it.Read the article →Summary
In July 2026 the Deputy Transport Minister told the Dewan Rakyat that private drivers do not face an extra health check from the age of 70, citing a MIROS study and international analysis that found no conclusive evidence that such checks cut accidents. This article asks what a share of crashes can and cannot tell us, and why the question belongs to the consulting room more than the licensing counter. It looks at what Malaysian law asks of drivers today, why age is a poor lever, and what function looks like in practice: vision, thinking, sugar and sleep, and medicines. It then asks who a doctor tells when a driver refuses advice, makes the strongest case for an age threshold, and ends with what I would do. It is careful about the difference between a share of people involved in crashes and the risk to a driver, and between a test that is required and a test that works.
The question is not how old you are. It is whether you can still do it, and who will tell you when you cannot.Read the article →Summary
Ebola brings back memories of the West African epidemic of 2014–2016, and many readers assume the vaccines and treatments developed since will work whenever it returns. They may not, because Ebola is not just one virus. This article looks at the Bundibugyo virus behind the current outbreak in the Democratic Republic of the Congo, where WHO reported 9,704 confirmed cases and 4,687 deaths as of 20 October 2026. It covers where the virus comes from and how it spreads, the early signs that can be mistaken for malaria or dengue, and why supportive care matters when no Bundibugyo treatment is approved. It then asks why the vaccine gap matters: Ervebo is licensed for Ebola virus, not Bundibugyo, the cross-protection evidence is limited, and the Tumaini Phase 2/3 trial began in Bunia on 23 October. It ends with Malaysia’s preparedness. It is careful about the difference between a crude case-fatality ratio and an individual’s risk, and between a licensed vaccine and one shown to protect against this virus.
Preparedness begins with understanding the disease—not with alarm.Read the article →Summary
In October 1951, a cancer patient in London, Ontario received the first clinical treatment from a cobalt-60 machine, soon nicknamed the “cobalt bomb”. This article follows that technology to Malaysia. It starts in the Dewan Ra’ayat on 26 April 1961, when the Minister of Health said the new Kuala Lumpur General Hospital’s cancer unit would be equipped with a cobalt-60 machine, and with Dato’ Dr S.K. Dharmalingam, the country’s first Malaysian consultant radiotherapist. It then looks at the Institute completed in 1968, the Penang machine paid for by community donors and installed in 1979, the spread of radiotherapy to Sarawak, and why linear accelerators took over. It also asks why cobalt-60 has not disappeared, from Gamma Knife radiosurgery to the calibration of dosimeters for 42 radiotherapy centres, and what a source that stays radioactive demands of those who keep it.
A sophisticated machine does not treat a patient if it is unavailable, broken down, inadequately staffed or too far away to reach.Read the article →Summary
In October 1999, 46 boys and young men were admitted to hospital after swimming in a creek in Beaufort, Sabah, and one died. Within days the outbreak was being discussed on ProMED. This article goes back to the record: what the early postings suggested, what the serology showed, and what the published investigation concluded. Twenty-seven years on, the Ministry of Health reported 2,445 laboratory-confirmed leptospirosis cases in 2024, and 876 melioidosis cases with 139 deaths. It asks why both infections are still overlooked, from floodwater and freshwater recreation to diabetes and access to a laboratory, and what the global estimates and the Darwin study add. It is careful about the difference between a serological signal and a diagnosis, and between a reported count and the true burden.
The test, twenty-seven years on, is whether it reaches the next boy at the creek in time.Read the article →Summary
A signature on an insurance form can authorise more than most patients realise. Part 2 of 2 asks who controls disclosure once medical information leaves the hospital: what consent to an insurer does and does not cover, what a doctor’s report should contain, what the MMC guidelines and the PDPA provide, and what happens when information crosses borders. It is careful about the difference between professional guidance and an enforceable right, and between a medical report and the whole medical record.
A signature on an insurance form should begin an informed process of disclosure. It should not end the conversation about confidentiality.Read the article →Summary
Who owns your medical records: the hospital that keeps them, the doctor who writes them, or the patient whose illness they describe? Part 1 of 2 separates three things that are often confused: ownership of the original record, custody of it, and the patient’s right of access. It sets out what the MMC guidelines, the private healthcare regulations and the PDPA provide on access, correction and portability. It is careful about the difference between a medical record and a medical report, and between an ethical duty and a statutory right.
Information should follow the patient safely.Read the article →Summary
Malaysia has asked the WHO to consider an urgent pilot in which countries buy selected medicines together. This article asks whether buying together actually works: what the WHO’s own exploratory paper says, what the evidence on pooled procurement shows, and where programmes have stalled or disappointed. It proposes two lanes, tendered generics first, then an open tender followed by negotiation for costly originator and specialised treatments, and sets both beside what Malaysia’s public sector has paid. It is careful about the difference between a proposal and an agreed mechanism, and between a price saved and medicines supplied.
Success should not be measured by how much governments announce they have saved, but by whether patients get safe, effective medicines when they need them.Read the article →Summary
Malaysia’s National Cancer Registry shows that, among cancers with a recorded stage, 64.8% were diagnosed at stage III–IV in 2017–2021, and stage is missing for more than half of registered cases. This article looks at what the registry does and does not show, why diagnosis is delayed, what screening can and cannot do, and how Malaysia’s targets compare with other countries. It is careful about the difference between a share of staged cancers and a share of all cancers, and between a policy target and a result.
Earlier diagnosis requires both informed patients and an accountable, accessible health service.Read the article →Summary
A heart attack leaves scar where muscle used to be. Twenty-five years after the first bone-marrow cell treatments, including those at Malaysia’s National Heart Institute (IJN), this article asks whether damaged heart muscle can now be replaced and not only protected. It looks at what the larger trials and a 2024 Cochrane review found, at iPS-cell-derived heart cells and Japan’s conditional approval of RiHEART in March 2026, and at Germany’s engineered heart muscle, BioVAT-HF, an early study with no control group. It is careful about the difference between a trial signal and proven benefit, and between conditional approval and clinical benefit.
Today we are asking whether we can manufacture the myocardium that the patient has lost.Read the article →Summary
The next pandemic will not wait for governments to finish negotiating. This article asks who will have access to the response: where the WHO Pandemic Agreement and its Pathogen Access and Benefit-Sharing (PABS) annex stand, what COVAX taught us, and whether Malaysia can make its own vaccines. It is careful about the difference between a negotiating target and a treaty in force, and between planned facilities and operational vaccine production.
The next pandemic will test not what the world promised, but what it actually prepared.Read the article →Summary
Hair loss may affect confidence and quality of life, but it is not always a condition requiring surgery. This article asks whether a transplant that looks good at twelve months is still safe and satisfactory years later. It covers diagnosis, what success rates really mean, the risks of medical tourism, and how to check the procedure, practitioner and premises in Malaysia. It is careful about the difference between graft survival, visible growth and patient satisfaction, and between a lower price and lower quality of care.
The most useful measure of success is not the photograph taken at twelve months, but how naturally and safely the result serves the patient over time.Read the article →Summary
Cholesterol treatment usually means tablets, or injections repeated for years. This article asks whether one infusion could change the liver’s instructions and keep LDL cholesterol lower long after the medicine has gone. It looks at what the 2026 NEJM Phase 1 report of VERVE-102 in 35 adults showed, the safety questions, and why irreversibility raises the bar. It is careful about the difference between biological activity and proven benefit, and between an early trial result and fewer heart attacks.
The experimental approach still has to prove that patients live longer or live better.Read the article →Summary
A man has had a cough for three weeks, and puts off the clinic until the queue is shorter. Everything in the tuberculosis figures begins with someone deciding whether to go. This article asks whether the line is moving at all, with notified cases within roughly 25,000 to 27,000 a year since 2022, and sets the “TB-free by 2035” vision beside the targets and treatment guidelines. It is careful about the difference between notified cases and modelled incidence, and between a guideline and what is used in clinics.
The next number to watch is not this week’s. It is whether the line ever bends.Read the article →Summary
For a child with severe thalassaemia, the hospital calendar can become part of childhood. This article explains the difference between adding a gene and editing one, where gene therapy has reached patients, and what a single-arm trial does and does not establish. It then turns to Malaysia: the NPRA guideline, the MACGT registry, and why approved does not mean accessible. It is careful about the difference between an overseas approval and Malaysian registration, availability or funding.
It matters when it changes the life that follows.Read the article →Summary
Budget 2027 gives the Ministry of Health RM47.7 billion, up RM1.18 billion (about 2.55%) from 2026, but almost all of the increase is operating expenditure. This article asks how we make every ringgit count: what the Estimates show, where leakages and wastage arise, and what the district can teach about letting managers manage. It is careful about the difference between a commitment and an outcome, and between what was allocated and what was actually spent.
The success of Budget 2027 should ultimately be judged not by how much KKM spends, but by what improves — for patients, healthcare workers and the population.Read the article →Summary
A glucose result can take over a consultation. This article asks what is missed when it does. NHMS 2023 estimated that 15.6% of Malaysian adults had diabetes, roughly two in five of them unaware. It looks at what the waist tells us that BMI does not, what the Malaysian obesity guideline already says about the tape measure, and the case for earlier diagnosis and better control, including continuous glucose monitoring. It is careful about the difference between a research cut-off and a clinical recommendation.
Diabetes is a glucose diagnosis. It is rarely a glucose problem alone.Read the article →Summary
Clinical trials were being conducted in Malaysia long before there was a system to support them. This article follows how the ecosystem was built: the Clinical Research Centre network, the national ethics and registry machinery, Clinical Research Malaysia, and the move into first-in-human research. It asks whether the trials came, and whether success should now be measured by the research that begins here. It is careful about what the figures do and do not show: CRC/ICR and CRM figures are different measures that cannot simply be added.
The next measure of Malaysia’s success should not simply be how many global trials come here. It should be how much important research begins here.Read the article →Summary
Aesthetic medicine used to add, remove, tighten or relax. Now it promises that tissue will repair itself, under the banner of regenerative aesthetics. This article asks whether we can really make ageing skin younger, going through PRP, polynucleotides, PDRN, exosomes, secretomes and stem cells, and the questions to ask in Malaysia before anyone injects “regeneration” into your skin. It is careful about the difference between looking younger and being biologically younger, and between a regulatory label and evidence that it works.
Improving an aesthetic outcome is credible in some settings. Reversing biological ageing is a much less established claim.Read the article →Summary
Artificial intelligence is moving beyond answering questions to producing mathematical results, proposing hypotheses and designing potential medicines, but generating a promising result and establishing a discovery are not the same thing. This article asks whether AI can contribute genuinely new scientific knowledge, from AlphaFold 3 and rentosertib to the virtual-cell effort, and what it could mean for Malaysia. It is careful about the difference between a hypothesis and a fact, and between a result generated by AI and one that survives independent scrutiny.
AI may help us discover what we did not know. Science must still establish whether what we have discovered is true.Read the article →Summary
Medical AI can now answer examination questions and draft differential diagnoses with impressive fluency, so how good is it, really? This article looks at the Medical AI Superintelligence Test (MAST), whose general leaderboard, last updated on 8 October 2026, puts the leading general-purpose models at around 60%, with the highest composite at 60.2%, and asks what that number does and does not mean. It is careful about the difference between answering structured questions and improving outcomes in real patients, and notes that the leaderboard is still in preview.
Medicine is not a single cognitive task—and intelligence is not a single score.Read the article →Summary
How did a company founded in Pune in 1966 become so important to global immunisation, and what can Malaysia learn from its experience? I first heard of the Serum Institute of India (SII) during my Aventis years and met it again as a regional partner at Novavax, and my one regret is that I never visited its plant in Pune. This article follows SII from antitoxins and antivenoms to routine childhood vaccines, and looks at why affordability and quality-assured supply matter, MenAfriVac and MenFive in meningitis, the company-reported donations, its COVID-19 role through Covishield and Covovax, and the R21/Matrix-M malaria vaccine developed with Oxford and Novavax. It then turns to the economics of vaccine manufacturing and what Malaysia and ASEAN can realistically take from a capability built over decades, including the difference between fill-and-finish and end-to-end development. It is careful about the difference between company-reported figures and independently verified ones, and about the difference between developing, manufacturing and distributing a vaccine. It carries an editorial independence and disclosure statement.
The real measure is not simply the number of doses produced. It is whether safe, effective, quality-assured vaccines reach the people who need them.Read the article →Summary
When a child is obese, is it the child, the parents, the environment, or has obesity itself become the disease? On 7 October 2026 the World Health Organization released its first global guidelines on the integrated management of obesity in children and adolescents, and NHMS 2024 found that more than one in four Malaysian children and adolescents aged 5–19 were overweight (14.4%) or obese (13.6%). This article looks at how childhood obesity is defined, why blame is such a poor treatment, the part played by biology, families, schools and the wider environment, the growth-chart clues that should prompt a search for another cause, the complications and stigma that come with it, and what structured, family-based care involves at different ages. It then turns to the new obesity medicines, including why an overseas approval is not a Malaysian indication, their side effects, and the narrow place of bariatric surgery in severe adolescent obesity. It is careful about the difference between WHO’s international guidance and what Malaysian product information and the 2023 national guideline actually say.
Treat the disease. Support the family. Change the environment. Protect the child.Read the article →Summary
The 2026 Nobel Prize in Physiology or Medicine recognised optogenetics, and I admit my own tube light did not quite go on at first. This article follows the story from a single-celled green alga to channelrhodopsin, the light-gated channel that Nagel and Hegemann helped establish, and then to the 2005 experiment that put it into mammalian neurons. It explains what optogenetics is, why it changed neuroscience, and what it has taught us, and looks at the one clear human proof-of-concept, partial visual recovery in a patient with advanced retinitis pigmentosa. It asks why the eye came first, why treating the brain is so much harder, and why the larger legacy may be indirect, with discoveries made with light guiding other treatments. It is careful about the difference between understanding a disease circuit and treating a patient.
Optogenetics does not necessarily have to become the treatment to change the treatment.Read the article →Summary
A British newspaper has described an “American COVID” variant spreading in the United Kingdom, with a list of symptoms attached. The label is misleading, and the more interesting story lies elsewhere: SARS-CoV-2 continues to evolve, vaccine manufacturers can update their products to circulating lineages, and yet the surveillance that should inform those decisions has become less comprehensive. This article looks at the XFG lineage and what a share of submitted sequences can and cannot show, why a variant is not a nationality, how WHO’s retention of LP.8.1 sits beside the XFG choices of the US FDA and the European Medicines Agency for 2026–2027, what antigen selection means for the manufacturers who must plan around it, how mRNA and recombinant protein platforms compare, and what all of this means for Malaysia. It is careful about the difference between a share of sequences and a share of infections.
We are getting better at updating vaccines. Are we becoming less certain about what the virus is doing?Read the article →Summary
Scams and online abuse in Malaysia, set out as a practical guide. Bank, government and family impersonation, phishing and malware, investment, shopping and job scams, love scams, sextortion and AI-fabricated images, and cyberbullying: for each, what to do before it happens and what to do after. The first minutes after money is sent (the bank, its Kill Switch, NSRC 997 and a police report), the checks that help, how families can respond without humiliation, a safety plan for older people and those living alone, a contacts table, and where Malaysian law stands. It is careful about the difference between a law that has passed Parliament and a law in force: at 7 October 2026 a gazetted commencement date for the Cybercrimes Bill 2026 could not be verified.
Before you press send, make one independent call.Read the article →Summary
A 28-year-old laboratory worker at the Irkutsk Anti-Plague Research Institute died on 2 October after developing pneumonia of unknown aetiology. WHO is looking at possible pneumonic plague; Russia has told WHO that no plague cases have been recorded in Irkutsk. Plague was being considered. It had not been confirmed. This article is about the stage before the diagnosis: what “unknown origin” means, how clinical assessment, exposure history, laboratory testing and contact tracing fit together, why precautions and treatment may begin before confirmation, and why nearly 200 contacts were placed under observation. It also looks at Wu Lien-Teh, the Penang-born doctor who confronted the Manchurian pneumonic plague epidemic of 1910–11, Malaysia’s own plague history and notification rules, and what we still need to know. It is careful about the difference between a signal, an investigation and a diagnosis.
The absence of a detected outbreak and the absence of an explanation are different findings.Read the article →Summary
In July 2006 I wrote about medical research and the Ninth Malaysia Plan. Twenty years later, this article asks three questions: what did we build, what did we learn, and what did it change? It traces the foundations, from the first Malaysian Good Clinical Practice guideline in 1999 to the national research register, Clinical Research Malaysia and the Institute for Clinical Research, then sets that machinery beside what the national health surveys show: overweight and obesity, diabetes and hypertension are still with us. It looks at the distance between research and better health, what COVID-19 and the vaccine ambition tested, and Malaysia’s move upstream into early-phase research. It is careful about what study counts and survey figures can and cannot show.
What are we doing with what we know?Read the article →Summary
A bottle, a shirt and a car tyre belong to the same story: plastic that fragments or sheds into particles and travels through water, food and air. Particles have been reported in human blood, brain tissue and arterial plaque, and a 2024 study linked plaque plastics with later heart attack, stroke or death. This article sets out what those studies show and what they cannot, with Malaysian bottled-water and semen studies, the seafood question, why there is no clinical test and what a doctor should say, and then returns upstream to what households, industry and government can prevent. It is careful about the difference between a policy target and a result.
How much of it needed to get there in the first place?Read the article →Summary
Vads Corner went online on 12 October 1995, Cybermed began in Berita MMA in March 1997 and Kerbside Consult in August 2026. Asked how much I have actually written, I counted — and found that reading the old pages was more interesting than counting them. A personal retrospective on getting online when that was itself a task, on building a one-stop site for medical resources, on columns that aged better or worse than others, and on why the question has moved from finding information to deciding what it means. It is careful about what the counts do and do not include: indexed columns and pieces, not a complete lifetime bibliography.
There is probably another article in that.Read the article →Summary
Twenty billion ringgit is large enough to become almost meaningless. On 9 July 2026 the Government told Parliament that, after RM31.3 billion in recoveries and assuming no further recoveries, the remaining net burden of 1MDB-related obligations is about RM20.1 billion. This article translates that figure into the scale of Malaysian healthcare and of an ordinary household: about 43% of one year's Ministry of Health allocation, almost three times its development budget, the equivalent of some 428 clinics the size of the one planned for Rantau, and roughly RM584 for every person in Malaysia. It is just as careful about what the comparison is not: there is no evidence this money was ever earmarked for healthcare, and the figures illustrate scale, not loss.
At the kerbside, it is opportunity. And opportunity has a cost when it is lost.Read the article →Summary
In December 1997 I wrote about a bird virus that had crossed into humans in Hong Kong. Since then there have been two pandemics, and neither was the H5N1 we were watching: the first was a swine-origin H1N1, the second was not influenza at all. Today H5N1 is still with us, and an October 2026 paper in Emerging Infectious Diseases points to reassortment in older Asian lineages as a possible, but unproven, driver of spillover. This article asks what reassortment is, why most of it goes nowhere, what the evidence does and does not show, and whether Malaysia's animal, environmental and human surveillance connects quickly enough.
We do not need to predict the next pandemic perfectly. We need to be ready when the virus reveals itself.Read the article →Summary
Reports of medical officers not reporting for permanent postings in Sabah and Sarawak invite blame, but the figures are still provisional until the 7 October reporting deadline. This article asks a better question: how do we make doctors want to go, and make it worthwhile for them to stay? It looks at the family, postgraduate training, connectivity, the cost of an empty post and what a rural medical officer offer worth accepting might look like.
Compulsion may get the doctor to report. Opportunity, support and belonging may make the doctor stay.Read the article →Summary
Malaysia’s Fifth Edition of Good Clinical Practice is a reason to look back. From ICH E6 and Malaysia’s first national guideline in 1999, through E6(R2)’s focus on risk, to E6(R3)’s quality by design, this article traces how GCP changed what researchers are expected to plan and oversee in a trial, and why the purpose has not changed: protecting participants and producing trustworthy evidence.
Good Clinical Practice was never meant to mean more paperwork. It was meant to mean better research.Read the article →Summary
Twenty years after Yamanaka showed that an adult cell could be reprogrammed, iPS-derived cells are being used to make heart muscle, replace dopamine-producing neurons, manufacture platelets and engineer immune cells to attack cancer. This article looks at what has reached patients, what Japan's 2026 conditional approvals do and do not establish, and why making the right cell, consistently and safely, is the real challenge.
The future of medicine may not only be about finding the right drug. It may also be about manufacturing the right cell.Read the article →Summary
El Niño is forecast to return, and Malaysia has been here before. The 1997–98 and 2015–16 events brought drought, haze, heat and water stress, and the health consequences extended well beyond the weather itself. This article looks at what those episodes taught us about heat illness, dengue and other vector-borne disease, haze, water and food security, and what households, clinicians and health services can do to prepare.
The climate hazard may be natural. The size of the health disaster is not predetermined.Read the article →Summary
West Nile virus is making news in Italy again, with more than 1,500 locally acquired human infections reported across 16 European countries. Twenty-seven years after the 1999 New York outbreak, the question for Malaysia is closer to home: researchers have reported viral RNA in our birds, mosquitoes, bats and horses, but what that means for human illness is much less certain. Why the animal, mosquito and patient findings need connecting, and what clinicians and laboratories can do before an outbreak.
Do not wait for the outbreak. Connect the animal, mosquito and patient findings, and test what is suspected.Read the article →September 202629 articles
Summary
Consumer genetic testing can illuminate ancestry, reconnect families and reveal medically important information. It can also contradict the documentary family tree, uncover relationships no one expected and allow an untested person to be narrowed to a likely identity through relatives. This article examines autosomal DNA, Y-DNA, mitochondrial DNA and SNPs — and the questions they raise about health prediction, consent, ownership, security and genetic privacy.
Your genome may be uniquely yours. The information contained within it has never belonged to you alone.Read the article →Summary
A 31-year-old man from Kubang Pasu was reportedly bitten by a stray dog in August, did not receive post-exposure prophylaxis, and died of rabies — the first human case in Kedah since 1998. This article sets the case against Malaysia’s rabies history and Sarawak’s continuing outbreak, and explains the first consultation, vaccine and immunoglobulin, the window after exposure, and what prevention needs from health services, veterinarians and communities.
Every bite deserves an assessment. Every community deserves prevention.Read the article →Summary
The science and business of longevity — what biological clocks, experimental medicines and supplements can tell us, what human trials have actually shown, and which established measures help protect health and independence. An examination of healthspan, lifespan and the evidence behind the promise of more healthy years.
A longer life is valuable largely because of what can still be done with it.Read the article →Summary
Memory may change with age. Dementia is different: it causes an acquired decline that interferes with independent everyday life. This article explains the warning signs, treatable mimics, assessment and treatment, sundowning, caregiver support, care choices and advance planning — with Malaysian services and practical guides for families.
A diagnosis may explain the behaviour, but it must never erase the person.Read the article →Summary
Hearing loss in later life can mimic memory trouble, deepen isolation and increase risk. This article examines when hearing loss needs urgent assessment, how tinnitus and hearing aids fit into the picture, what devices cost in Malaysia, what financial help may be available, and what families can do today.
Sometimes restoring connection begins with four ordinary words: Can you hear me?Read the article →Summary
Malaysia’s concessions begin at 60; its demographic statistics turn at 65. Neither threshold is a clinical finding. What actually separates a manageable later life from dependence — savings, family, surroundings — and why clinicians and policy alike should treat the person in front of them, not the birthday on the file.
It is an age — not an answer, a retirement from relevance, or a diagnosis.Read the article →Summary
On 15 September 2026, Fiji declared HIV a national emergency — an estimated 9,100 people living with it, only 39% aware of their status and 22% on treatment, and new diagnoses up 27% in a year. What accelerated a preventable epidemic, what it says about mother-to-child transmission, prevention and access to treatment, and what Malaysia and the region should take from a warning that has no national boundary.
HIV never left. We should not wait for a national emergency to notice it again.Read the article →Summary
Malaysia has legislation, national guidelines, surveillance and an action plan on antimicrobial resistance. The unresolved question is whether these reach the consultation room and pharmacy counter — and whether anyone measures what happens there. The evidence, the implementation gap, and what clinicians and pharmacists can do.
The laboratory report may say “resistant”. What it is really telling us is that choices made before this patient arrived now matter.Read the article →Summary
Medicine needs hierarchy, but hierarchy also creates power. This piece examines Malaysian evidence on workplace bullying, protected reporting, due process, the role of witnesses and the hidden curriculum through which one generation teaches the next what medicine will tolerate.
Authority is not immunity. A good hierarchy uses the knowledge of the senior person while protecting the dignity of the junior one.Read the article →Summary
In 1999, an unfamiliar mosquito-borne illness appeared in Port Klang and I asked whether we were doing enough to control vector-borne diseases. Twenty-seven years later, chikungunya has spread through Asia and the Americas, vaccines have arrived and been suspended, and the mosquito looks very familiar. The challenge is no longer finding the tools. It is using them together.
The challenge is no longer finding the tools. It is using them together.Read the article →Summary
In late 1998, Malaysia thought it knew what was killing the pig farmers. It was Japanese encephalitis — until the patients, the epidemiology and the pigs themselves stopped fitting the diagnosis. How Malaysian clinicians, scientists and veterinarians recognised that a reasonable diagnosis had accumulated too many unreasonable exceptions, and what they found when they looked harder. The discovery of Nipah virus, told through contemporaneous DOBBS and Cybermed archives.
When the facts stop fitting the diagnosis, question the diagnosis — not the facts.Read the article →Summary
Sarawak, Taiwan and what outbreaks taught us about information, uncertainty and trust — from the early medical Internet, when reliable information was scarce, to a world where information is instantaneous and certainty can travel faster than evidence.
We solved the problem of getting information quickly. We did not solve the harder problem of knowing how much confidence that information deserves.Read the article →Summary
Workplace violence in Malaysian healthcare — what local studies reveal about abuse and under-reporting, where compassion and staff safety meet, and what healthcare professionals, patients and relatives can do before anger becomes violence.
You can challenge the care without threatening the caregiver.Read the article →Summary
Two of the world’s largest measles outbreaks in 2026 arrived by entirely different routes — one through disrupted immunisation systems and widening coverage gaps, the other substantially through declining vaccine acceptance. Malaysia, with neither crisis, had 231 outbreaks in 2024 anyway. As of 14 September 2026: Bangladesh has recorded more than 172,000 suspected cases and 1,030 deaths; the United States has recorded 3,294 confirmed cases, its highest annual total since eliminating measles in 2000. The article asks how three very different settings ended up in the same place, and what that means for Malaysia specifically. With acknowledgement to Prof Lam Sai Kit for review and suggested additions. Updated 9 November 2026 with Bangladesh and US surveillance figures and six dated corrections, logged in the article.
Coverage numbers are averages, and measles does not respect averages. It finds the unprotected fraction.Read the article →Summary
A practical one-page guide for patients, parents, and anyone who needs to act now — from isolating immediately and recognising Koplik’s spots, to vitamin A dosing, urgent warning symptoms, household contact management, and notifiable disease reporting. Companion to Eliminated, Until It Wasn’t.
Do not walk into a clinic or emergency department without calling ahead.Read the article →Summary
A pre-travel MMR checklist for Malaysian families — vaccination status by birth cohort, what to do with infants aged six to eleven months, the concluded 2025 MOH supplementary campaign, post-exposure steps abroad, and why Malaysia itself is on the CDC’s global measles advisory list. Companion to Eliminated, Until It Wasn’t.
In 2026, there is no low-risk itinerary for an unvaccinated traveller.Read the article →Summary
Twenty-six years ago, medicine stood at the edge of a genetic revolution. Reading back the genome project optimism of 2000, David Quek’s ethics editorial and Ronald McCoy’s Sandosham Lecture from 2026: some predictions proved remarkably prescient, others never happened, and the ethical questions behind them have become more pressing as gene therapy, CRISPR and genetically edited pig kidneys move from speculation into regulated medicine. Malaysia is now sequencing its own population. The problem is rarely whether science will advance.
It is whether our judgement can keep up.Read the article →Summary
From traditional medicine to wellness technology — how do we know whether a treatment really works? Artemisinin showed that traditional knowledge can supply a real clue to a real medicine. The RM17,000 electrostatic machine showed that an impressive-sounding explanation is not the same as evidence. Acupuncture sits somewhere in between — better than sham for chronic pain in some well-conducted trials, insufficient evidence for most of the conditions it is marketed for. The 1997 editorial that started this piece, the 2005 column that prompted it, and nearly thirty years of the same question: does it work, is it safe, and where is the evidence?
The packaging is different. The yardstick is not.Read the article →Summary
The traditional consultation was built around an enormous imbalance of information. The Internet disrupted that hierarchy. Patients could suddenly read about their illnesses before seeing their doctors. Social media changed the quality of what came through the pipe. Defensive medicine added an invisible participant to every encounter. And now generative AI has entered the room too — not as a tool the doctor chose, but as something the patient brings in. Thirty years of watching one part of this transformation, from Vads Corner in October 1995 to the consultation as it stands today.
The information gap is narrowing. The judgement gap may be much harder to close.Read the article →Summary
From Nipah and West Nile to H5N1 and antimicrobial resistance — thirty years of warnings, and the lessons we keep relearning. Each outbreak taught something different: about spillover, ecological surveillance, watching transmission change, healthcare amplification, system resilience, and threats that advance without an obvious starting gun. The question is not which pathogen comes next. It is whether the systems to detect and respond to it are in place when the warning arrives.
We cannot know what comes next. But after nearly thirty years of warnings, we should know what to do when it comes.Read the article →Summary
The patient may still see the doctor. Increasingly, the consultation begins somewhere else. Generative AI has moved from novelty to clinical adjacency faster than medicine has moved to understand it. This piece examines what AI can do well, where it fails in ways that matter, what the clinical trials actually show, and what both patients and doctors should do when the machine has already had its say.
The information revolution has become an interpretation revolution. The question is not whether AI belongs in the consulting room. It is already there. The question is where it should sit.Read the article →Summary
Malaysia has demonstrated through RESET that it can build high-level political machinery — a joint ministerial committee, named insurers, a live pilot, regular progress reporting — around a difficult healthcare problem. The government’s Health White Paper, passed by Parliament with bipartisan support in 2023, is a comprehensive 15-year reform blueprint for the public healthcare system. It has not received comparable machinery. This piece asks why, and what the evidence from eight sections of primary sources looks like when placed alongside that question.
67% of hospital admissions and 83% of outpatient visits go through the public system. That is the system the Health White Paper is for. That is the system this piece is about.Read the article →Summary
Malaysia measures hourly PM2.5 concentrations at 68 stations. It publishes a composite index. It does not publish the underlying concentration in the unit that WHO guidelines, commercial apps, and Singapore’s own system use — and the gap between those two things has a clinical cost that is measurable in hours, not days. This argument has been made from this column since 1999. The previous version of it was eventually won.
The question is whether the next step takes another decade, or whether someone finds the courage this season.Read the article →Summary
Malaysia’s proposed Senior Citizens Bill is delayed again — now expected in early 2027. But the delay is the least of the problem. A law that passes without funding, enforcement machinery, community detection and care infrastructure will not protect elderly Malaysians. It will offer them rights on paper. Four million people aged 60 and above, at least five ASEAN neighbours with dedicated legislation already in force, and an Act that has been on the books since 2018 and has never once been brought into force.
The law is the beginning of the answer, not the answer itself.Read the article →Summary
Malaysia’s new government-backed base medical insurance product has a design problem. It is described by ministers as protection for people the private market fails. It is built, in its actual terms, as a fully underwritten voluntary insurance product. A comparison of six countries across the Asia-Pacific shows that the choice Malaysia has made in MediAsas is not the only available one — and a nationwide survey of 855 specialists reveals what happens when a guarantee letter exists on paper but not at the point of need.
A promise made at the point of sale — protection, if you need it — is not the same as protection delivered at the point of need.Read the article →Summary
A practical one-page guide to disputing a denied, delayed or revoked health insurance claim in Malaysia — from getting the reason in writing to filing a free dispute with FMOS. Plain, practical, and printable.
A free, independent dispute body has existed since January 2025. Most patients still do not know to use it.Read the article →Summary
Thirty years of building this without a budget, an institution, or anyone asking me to — and the question that Kerbside Consult has finally made it hard to avoid asking directly.
Whether the next ten years justify the same verdict is not mine to decide.Read the article →Summary
GP consultation fees frozen since 1992. Hospital non-professional charges unregulated. A public alternative running short of the workforce needed to deliver it. Malaysia regulates most tightly where costs are already lowest, leaves pricing freedom where bills are largest, and is underinvesting in retaining the doctors the low-cost option depends on.
The RM80 regulatory ceiling and the RM34 consultation rate a GP actually receives are not in conflict with each other. They coexist.Read the article →Summary
What thirty years of guestbook correspondence actually recorded — who was using the site, why they had come, and what they did with what they found there.
People wrote back. That seems as good a measure as any of whether it was worth doing.Read the article →August 20266 articles
Summary
In 1997 I wrote about the computer a doctor would need to get online, and about a law that would let doctors practise medicine down a telephone line. The computer became obsolete on schedule. The law never started. What the evidence actually says about telehealth today, what already exists scattered across six different systems nobody has joined up, and what it would take to finish what was promised twenty-nine years ago.
Malaysia rebuilt a 1997 cyber law from scratch this year. Its sibling, passed the same year to enable telemedicine, has simply never been switched on.Read the article →Summary
The Bill has now missed five tabling dates, the carbon tax is under review, and the standard we are measured against is not law. What the evidence now says about heat and dengue, what the government has and has not done about it, and what the profession could do that it is not doing.
The consultation on the Climate Change Bill drew submissions from lawyers, business networks and think tanks. None that I can find came from a medical body.Read the article →Summary
What to do about dengue: mosquito control that actually works, the warning signs that mean see a doctor, the ones that mean go to hospital now, and one common home-treatment mistake that makes bleeding worse. One screen long, and printable.
The dangerous phase isn't while the fever is high. It's the day or two after it breaks — exactly when people stop paying attention.Read the article →Summary
A dengue vaccine is registered, available, and being bought privately in Malaysia. The question was never whether it works. It is what a cost-benefit analysis actually assumes, who decides, and why the same regulatory meeting can be reported two entirely different ways by two professional bodies who each took what they wanted from it.
Two doses run at RM400 to RM500 in private clinics. A family that can find that much is protected this month. A family that cannot waits for an analysis whose assumptions are not published.Read the article →Summary
What to do about the haze. Which mask actually works and which is theatre, why closing the windows beats wearing one, who in your household is really at risk, and when to stop managing it at home. One screen long, and printable.
Only an N95 or better does anything. Fit matters more than the rating. And the bad chest arrives three days after the smoke clears.Read the article →Summary
The same haze, the same diplomacy, and a surveillance system that registers its own success as an absence of disease. Twenty years after I wrote HAZE-OC, the sequel writes itself — and that is rather the point.
Malaysia's ambient air quality standard turns out not to be law. The Ministry reported no rise in illness on a day nine Sarawak districts sat in the unhealthy band.Read the article →About Kerbside Consult
A kerbside consult is the oldest instrument in medicine. You catch a colleague in the corridor, describe the problem in ninety seconds, and get an honest answer without a referral letter. No fee, no formality, and — the part that matters — no reason to tell you what you want to hear.
That is what this is going to be. Medicine, public health and health policy, with a bias towards Malaysia and the region — outbreaks, climate and health, road safety, licensing and regulation, and the recurring distance between what the evidence says and what gets announced at a press conference.
New here? Start with Nine Weeks at the Kerbside, a guide to the archive by subject.
Who is writing
I am Dr Muruga Vadivale. Forty years in Medical Affairs across Asia-Pacific — Servier, Aventis and Sanofi across ASEAN, India and Korea; Celgene and BMS in haematology-oncology in Seoul and Taipei; most recently building the Asia-Pacific medical function at Novavax. I co-authored Malaysia's Good Clinical Practice Guidelines in 1999 and again in 2004, and founded the SITE cardiometabolic registry, which followed more than 18,000 subjects across eight states. There is more about me here, if you want it.
How I work
Claims get checked against the primary source, not against the newspaper's account of it, and not against a review's summary of a study. Where the evidence is genuinely contested, I say so rather than picking whichever side makes the tidier argument. These pieces are researched with AI assistance. Every factual claim is then checked by me against its primary source, and the sources are linked so you can check them too. The judgements, the arguments and the errors are mine.
Every piece ends with an annotated list of sources worth your own time. That habit is thirty years old and it is not going anywhere.
I have no commercial relationship with any party mentioned in these pages unless I say so in the piece itself. None of this is medical advice, and nothing here substitutes for your own doctor or for the judgement of the person actually treating you.
Corrections and right of reply
If you find an error here, please write to me. Every correction is checked. Where one is made, it appears at the foot of the article it concerns, with the date and a plain note of what changed. Corrections are not made silently. Anyone who points out an error is credited by name unless they would rather not be.
The same applies to anyone written about here. If you are named and believe something is wrong or unfair, write to me and I will look at it promptly. Where we simply disagree, I will publish your response alongside the piece, in your own words, provided it is signed.
The Cybermed Archive
Every column from March 1997 onwards is still online, exactly as published, dead links and all. Taken together it is a contemporaneous record of two decades of Malaysian outbreaks written as they unfolded, which is worth more than my tidying it up would be.
Dr Muruga Vadivale — "Cyberdoc"